Swedish ICU study reveals Long-Term COVID-19 outcomes
NCT ID NCT04462393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collected data from 7,500 adults admitted to Swedish ICUs with COVID-19 during the first two years of the pandemic. Researchers looked at patient characteristics, treatments, and survival rates at 30 days and one year. The goal is to understand the disease's impact and identify risk factors for death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Östergötland
Linköping, Östergötland County, 50185, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- AI may predict transfusion needs to shield ICU patients from organ failure
- A simple blood test trend may flag ICU patients at risk